Particle.news
Get it on Google Play
Download on the App Store
9 ARTICLES
·
4h ago

FDA Advisory Panel Narrowly Backs Grail’s Galleri Multicancer Blood Test

The committee’s split vote moves the test closer to possible FDA authorization and insurer review while leaving key questions about detection rates and long-term benefit unresolved.

Image
Dr. Sanjay Gupta undergoes a blood test that can potentially detect cancer.
The Galleri test's maker emphasizes that regular cancer screenings are still necessary.
Grail_Lab-Tour_FrameCaps_50-1-scaled-1

Overview

  • On Sept. 23 a 10-member FDA advisory panel voted that Galleri is safe (10-0), narrowly endorsed its effectiveness (6-4), and ruled 7-2 with one abstention that the test’s benefits outweigh its risks.
  • Galleri screens a single blood sample for tumor DNA to flag a possible ‘cancer signal’ rather than diagnose disease, and positive results require follow-up imaging or biopsy to confirm cancer.
  • Clinical data show very high specificity but modest sensitivity, detecting roughly 30–35% of cancers within 12 months and confirming cancer in about two-thirds of 'cancer signal detected' results.
  • Major evidence gaps remain: the large NHS-Galleri trial did not meet its prespecified one-year endpoint for fewer advanced-stage cancers and there is no direct evidence yet that the test reduces cancer deaths.
  • If the FDA follows the panel and authorizes Galleri in the coming months, coverage decisions by Medicare and private insurers could broaden access and sharply increase commercial uptake, which has already driven a strong post-vote stock rally.